Neurocritical Care News

WASHINGTON — Results presented here showed that college football players who wore dentist-fitted mouthguards had a lower incidence of severe concussions and faster return to sport compared with those who wore self-fitted mouthguards.

WASHINGTON — Among college football players who had concussions, researchers found players’ odds of an upper extremity injury were twice as great in the year after the concussion compared with the pre-concussion year.

BOSTON — With a multitude of products spanning neuroscience and psychiatry, executives at AbbVie say they are committed to learning the full clinical value of all of the company’s products for the benefit of patients.

In football-playing males, the number and force of repetitive head injuries as well as time playing the sport were linked to severity of chronic traumatic encephalopathy, according to research published in Nature Communications.

Edgewise Therapeutics Inc. announced positive 12-month topline results from the ARCH study evaluating the safety, tolerability and pharmacokinetics of EDG-5506 in adults with Becker muscular dystrophy.

Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years who have Friedreich’s ataxia, a rare degenerative neuromuscular disorder that manifests at a young age.

Horizon Therapeutics announced positive results of MRI data from the phase 3 clinical trial of Uplizna, which showed reduction in formation of subclinical transverse myelitis lesions in patients with neuromyelitis optica spectrum disorder.

The FDA has approved Rystiggo, a subcutaneous infusion therapy to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

The FDA has approved Elevidys, a recombinant gene therapy for pediatric patients with Duchenne muscular dystrophy and confirmed gene mutation who do not have a pre-existing medical reason preventing treatment.

Halozyme Therapeutics announced that argenx received FDA approval for Vyvgart Hytrulo with Enhanze for subcutaneous use in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.